Thyroid cancers after the Chernobyl accident; lessons learnt, an update.

Dillwyn Williams
Cambridge
What is the size of the increase in thyroid carcinomas and does it continue?

What are the uncertainties in assessing the size of the increase?

What is the estimated risk/Gy?

What factors affect the risk?

What are the changes with increased latency?

Are the molecular findings specific for radiation?

What should be the regulatory approach?

The future
The WHO/IAEA conference considering the first 20 years after the Chernobyl accident found that about 4000 cases of thyroid cancer could be attributed to the accident.

It was not made clear in the press release that this applied only to the most exposed areas.
Thyroid Ca in Belarus in those exposed to the accident, 1986-mid2006

<table>
<thead>
<tr>
<th>Oblast</th>
<th>Children</th>
<th>Adolescents</th>
<th>Adults</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brest</td>
<td>166</td>
<td>128</td>
<td>1523</td>
<td>1817</td>
</tr>
<tr>
<td>Gomel</td>
<td>382</td>
<td>234</td>
<td>2377</td>
<td>2993</td>
</tr>
<tr>
<td>Grodno</td>
<td>48</td>
<td>21</td>
<td>638</td>
<td>707</td>
</tr>
<tr>
<td>Minsk</td>
<td>45</td>
<td>33</td>
<td>1417</td>
<td>1495</td>
</tr>
<tr>
<td>Minsk City</td>
<td>67</td>
<td>41</td>
<td>2383</td>
<td>2491</td>
</tr>
<tr>
<td>Mogilev</td>
<td>45</td>
<td>31</td>
<td>1783</td>
<td>1859</td>
</tr>
<tr>
<td>Vitebsk</td>
<td>13</td>
<td>19</td>
<td>1601</td>
<td>1633</td>
</tr>
<tr>
<td>Belarus</td>
<td>766</td>
<td>507</td>
<td>11,722</td>
<td>12,995</td>
</tr>
</tbody>
</table>

From Bespalchuk et al, Nagasaki Symposium, 2007
Predictions for numbers of cases of thyroid cancer due to radiation occurring in Europe from 1986 to 2056


- 92,627. 26,584 of these predicted to lead to death. Malko, quoted by Yablokov and Nesterenko, 2009, Ann NY Acad Sci, 1181: 1-220
Uncertainties in assessing size of increase

- Increased ascertainment through screening, increased awareness, diagnostic advances
- Area covered
- Problems of diagnosis in peripheral hospitals
- Increasing PTC incidence in non-exposed areas
- Separation of radiogenic from background (baseline) incidence
Thyroid PTCs from Ukraine born after 1967. % of tumours 2cm or less by age at operation

Data from Tronko et al 2005, BMU 2005-668
What is the size of the increase in thyroid carcinomas and does it continue?

What are the uncertainties in assessing the size of the increase?

What is the estimated risk/Gy?

What factors affect the risk?

What are the changes with increased latency?

Are the molecular findings specific for radiation?

What should be the regulatory approach?

The future
Estimation of risk/Gy and factors influencing risk

- Dose, (RR 5.5-8.4/Gy (Cardis 2005))*
- Age at exposure
- Gender
- Environment
- Genetic susceptibility
- Time of assessment

*Very recent publication estimates ERR as 2.15/Gy (95%CI 0.81-5.47). Zablotska et al, BJ Cancer 23.11.10
Comparison of odds ratios (ORs) predicted by the best-fitting risk models with categorical odds ratios estimated in 11 dose categories

Incidence of thyroid cancer in Belarus.
Rate per 100,000

Data from Cardis et al 2006
Numbers of Thyroid Ca. in the highest and least exposed oblasts of Belarus by year of birth (<19 at op)

Data from Yu Demidchik 2005 BMU 2005-668
Thyroid Ca incidence rates for males in high and low exposure regions of Ukraine

Data from Fuzik et al, 2010, Rad Env Biophys; online 10.11.10
Thyroid cancer risk and I’ intake
Odds ratio, 1 Gy vs no exposure

From Cardis et al JNCI 2005
- What is the size of the increase in thyroid carcinomas and does it continue?
- What are the uncertainties in assessing the size of the increase?
- What is the estimated risk/Gy?
- What factors affect the risk?
- What are the changes with increased latency?
- Are the molecular findings specific for radiation?
- What should be the regulatory approach?
- The future
Changes with latency

- Clinical. Tumours are becoming less aggressive
- Pathology. More differentiated and smaller PTCs, less extrathyroid invasion, probable increase in follicular adenomas
- Molecular biology. Overall reduction in PTC rearrangements, fewer RET-PTC3 and more RET-PTC1
Extra-thyroid invasion (%) in PTCs, aged under 19 at exposure

Data from Tronko et al, 2005 BMU 2005-668
Thyroid Cancer Belarus
(data from Demidchik, GSF report, 2005)

The graph shows the number of cases of thyroid cancer over age at operation for different years:
- **Op '92**
- **Op '97**
- **Op '02**

The x-axis represents the age at operation, with values ranging from -4 to -34. The y-axis represents the number of cases, ranging from 0 to 80.
What is the size of the increase in thyroid carcinomas and does it continue?

What are the uncertainties in assessing the size of the increase?

What is the estimated risk/Gy

What factors affect the risk?

What are the changes with increased latency?

Are the molecular findings specific for radiation?

What should be the regulatory approach?

The future
Do the molecular findings provide a radiation marker?

- The great majority of PTCs from non-exposed areas show either a BRAF or a RET-PTC mutation, in children BRAF is less common.
- Chernobyl PTCs show fewer BRAF mutations than expected.
Major oncogene mutations identified in Papillary Thyroid Carcinomas

- RET. Activated by rearrangement to give a RET-PTC oncogene (c15 variants). RET-PTC 1 and 3 by far the most common
- B-RAF. Activated by point mutation, very nearly always V600E. Very rarely activated by rearrangement
- Others. Uncommon. TRAK rearrangements, RAS point mutations, unknown
Papillary Thyroid Carcinoma, genes and radiation dose

Data from Hamatani et al, 2008 Cancer Res 68 7176
These findings suggest that mutations due to double strand breaks are more common than point mutations as the initial event in radiation induced tumours.

This may be the only ‘molecular marker’ of radiation induced neoplasia.
- What is the size of the increase in thyroid carcinomas and does it continue?
- What are the uncertainties in assessing the size of the increase?
- What is the estimated risk/Gy?
- What factors affect the risk?
- What are the changes with increased latency?
- Are the molecular findings specific for radiation?
- **What should be the regulatory approach?**
- *The future*
A pragmatic approach to assessing the radiation risk to the thyroid

- The change in risk with age at exposure poses a problem.

- To include all under 14 in one category conceals wide variation.

- The evidence from Chernobyl suggests that those under 3 show much higher risks than older children, it is unclear how much of this is due to greater uptake.

- Studies of external radiation chose 0-4
On the basis of the current evidence it would seem sensible to subdivide the childhood risk into two groups, categorising young children as high risk, older children as medium risk, young adults as low risk, and older adults as undetectable or no risk.

This would have the advantage of ensuring that in any future accident measures to protect preschool children would be given priority.
A study should be commissioned to review all the Chernobyl related studies, to reanalyse using differing age groups to justify subdividing children into two groups. Risk/Gy is not the appropriate basis for determining this. A study of the risk to adults is also urgently needed, because of conflicting data. The evidence in relation to dietary iodine strengthens the need to eliminate I deficiency, and to consider long term iodine supplementation after exposure.
Conclusions

- Exposure to fall-out from Chernobyl has led to a very large increase in the incidence of thyroid carcinoma due to I’ radioisotopes.
- The risk is heavily dependent on age at exposure, and on stable iodine intake.
- Tumour morphology and molecular findings correlate and change with latency.
- Those exposed at a young age continue to carry the increased risk with them into adulthood.
Conclusions continued

- The risk continues in those who were young at exposure.
- Consideration should be given for regulatory purposes to define the risk for preschool children separately from older children.
- Although morbidity from thyroid cancer is high in the heavily exposed young children, mortality from thyroid cancer in those exposed to Chernobyl is currently extremely low.
Future studies

- Effects across Europe of low dose exposure
- Continuing study of the thyroid carcinomas to determine possible changes in tumour type and mutations, and length of outbreak
- Non thyroid studies, including inherited effects
- Follow up of children treated with high dose RAI
- Comprehensive and coordinated long term studies of the consequences of Chernobyl are needed: the EC should take the lead in setting up a Chernobyl Health Effects Research Foundation as a virtual equivalent to the RERF